Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abiraterone Acetate,[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=CC[C@@]21[H])C1=CN=CC=C1)OC(C)=O,Hyperbilirubinaemia,Human,-1.4471580313422192,Repeated,Oral,"EMA approval document: Assessment Report EMA/816845/2017; EMEA/H/C/002321/II/0047, page:62 PDF 2976k",https://www.pharmapendium.com/browse/ema/Abiraterone Acetate/86acf11df880ab20652cf1e1345955c2?reference=62,2017.0,[H][C]12CC=C3C[CH](CC[C]3(C)[C]1([H])CC[C]1(C)C(=CC[C]21[H])C1=CN=CC=C1)OC(C)=O
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N,Hyperbilirubinaemia,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210259/S-006; 210259/S-007 Part 16, page:21 PDF 7375k",https://www.pharmapendium.com/browse/fda/Acalabrutinib/efa223c1346a408063449cedd71ec87a?reference=21,2019.0,CC#CC(=O)N1CCC[CH]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019821, page:14 PDF 633k",https://www.pharmapendium.com/browse/fda/Acitretin/e52afb1fe8baa8e5ab992ef5ebed3ba5?reference=14,1994.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Hyperbilirubinaemia,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021449/S-000 Part 02, page:57 PDF 1758k",https://www.pharmapendium.com/browse/fda/Adefovir Dipivoxil/f59feb319af20abdd484a192c72a1024?reference=57,,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
Alectinib Hydrochloride,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N,Hyperbilirubinaemia,Human,-1.4471580313422192,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/833519/2017; EMEA/H/C/004164/II/0001, page:52 PDF 3057k",https://www.pharmapendium.com/browse/ema/Alectinib Hydrochloride/8ab8d439156bfc0390f0e486e2991bb9?reference=52,2017.0,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N
Allopurinol,O=C1NC=NC2=C1C=NN2,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018832, page:43 PDF 5594k",https://www.pharmapendium.com/browse/fda/Allopurinol/52fa5d08d3452a2974c3e85d74125655?reference=43,1984.0,O=C1NC=NC2=C1C=NN2
Amifampridine,NC1=CC=NC=C1N,Hyperbilirubinaemia,Human,-2.2430380486862944,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020932/S-000 Part 05, page:9 PDF 1500k",https://www.pharmapendium.com/browse/fda/Amifampridine/4ddaa96b28d6d1ece0eeb70141eba5a5?reference=9,2019.0,NC1=CC=NC=C1N
Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,Hyperbilirubinaemia,Human,0.0,Repeated,Intravenous,"FDA approval package document: Approval Package 050724 Part 01, page:54 PDF 6223k",https://www.pharmapendium.com/browse/fda/Amphotericin B/d0bf86ad757877fb6802e13c91e66f48?reference=54,1995.0,[H][C]12C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH](C)[CH](C)OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C](O)(C[CH](O)[CH]1C(O)=O)O2
Amphotericin B Liposome,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@H]1C)O2)C(O)=O,Hyperbilirubinaemia,Human,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 050740/S-002, page:31 PDF 1114k",https://www.pharmapendium.com/browse/fda/Amphotericin B Liposome/5901aee1119f21ffb118dbbaee8276f9?reference=31,1999.0,C[CH]1OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C]2(O)C[CH](O)[CH]([CH](C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH]1C)O2)C(O)=O
Amprenavir,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hyperbilirubinaemia,Human,-3.380211241711606,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 634k",https://www.pharmapendium.com/browse/ema/Amprenavir/af4bbc923d27123891d7d34e87c62e50?reference=13,2011.0,CC(C)CN(C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)O[CH]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/304231/2020; EMEA/H/C/000788/II/0040, page:57 PDF 3676k",https://www.pharmapendium.com/browse/ema/Anidulafungin/5a5991756b23170ddf3bf5cbcf6a6d04?reference=57,2020.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Hyperbilirubinaemia,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 021436/S-002 Part 01, page:45 PDF 399k",https://www.pharmapendium.com/browse/fda/Aripiprazole/ba6c7d04006a16f918aa4049f86d2f8e?reference=45,2004.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Arsenic Trioxide,O1[As]2O[As]1O2,Hyperbilirubinaemia,Human,-1.1760912590556813,Repeated,Intravenous,"EMA approval document: ANNEX I, page:9 PDF 275k",https://www.pharmapendium.com/browse/ema/Arsenic Trioxide/8fe81fd6c032913036bfbd33945a9dfa?reference=9,2020.0,O1[As]2O[As]1O2
Artesunate,[H][C@@]12CC[C@@]3(C)OO[C@@]11[C@@]([H])(CC[C@H]2C)[C@@H](C)[C@@H](OC(=O)CCC(O)=O)O[C@]1([H])O3,Hyperbilirubinaemia,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Label 213036/S-001, page:4 PDF 555k",https://www.pharmapendium.com/browse/fda/Artesunate/25eca5d1ff07104034b08c1687ae5066?reference=4,2020.0,[H][C]12CC[C]3(C)OO[C]11[C]([H])(CC[CH]2C)[CH](C)[CH](OC(=O)CCC(O)=O)O[C]1([H])O3
Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,Hyperbilirubinaemia,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019402 Part 04, page:24 PDF 3539k",https://www.pharmapendium.com/browse/fda/Astemizole/daa408184f093d0a73e56e0b2db38305?reference=24,1985.0,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1
Avapritinib,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/451735/2020; EMEA/H/C/005208/0000, page:112 PDF 6437k",https://www.pharmapendium.com/browse/ema/Avapritinib/a9be25284fcc55e1cf2294919763f338?reference=112,2020.0,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C](C)(N)C3=CC=C(F)C=C3)C2=C1
Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/453325/2012; EMEA/H/C/002406, page:73 PDF 1208k",https://www.pharmapendium.com/browse/ema/Axitinib/755c1be86b9ebb59766d67a496ec4500?reference=73,2012.0,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1
Azacitidine,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 214120/S-000 Part 08, page:12 PDF 1845k",https://www.pharmapendium.com/browse/fda/Azacitidine/919e5cd055151aafa9304eb0e463bfad?reference=12,2020.0,NC1=NC(=O)N(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Benazepril Hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019851/S-028 Part 01, page:5 PDF 896k",https://www.pharmapendium.com/browse/fda/Benazepril Hydrochloride/4f8ff320f464e197b44807e1d29ca46d?reference=5,2003.0,CCOC(=O)[CH](CCC1=CC=CC=C1)N[CH]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
Boceprevir,[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,Hyperbilirubinaemia,Human,-3.380211241711606,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 428k",https://www.pharmapendium.com/browse/ema/Boceprevir/3eded3dcf36e4c3ebdde3f8dd5fdd6aa?reference=13,2012.0,[H][C]12CN([CH](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C]1([H])C2(C)C)C(=O)[CH](NC(=O)NC(C)(C)C)C(C)(C)C
Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,Hyperbilirubinaemia,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/473644/2015; EMEA/H/C/000401 P46 081, page:23 PDF 1770k",https://www.pharmapendium.com/browse/ema/Bosentan/4881303780d3b0a323f67538312f312a?reference=23,2015.0,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1
Bosutinib Monohydrate,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 539k",https://www.pharmapendium.com/browse/ema/Bosutinib Monohydrate/137a7ce8622db12be304e68713ed1bbe?reference=11,2021.0,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
Brigatinib,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1,Hyperbilirubinaemia,Human,-2.255272505103306,Repeated,Oral,"EMA approval document: Assessment Report EMA/140650/2020; EMEA/H/C/004248/II/0003, page:73 PDF 5666k",https://www.pharmapendium.com/browse/ema/Brigatinib/90bc8094fb1cd300b7ee28bf690bb302?reference=73,2020.0,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,Hyperbilirubinaemia,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020954/S-000 Part 07, page:1 PDF 651k",https://www.pharmapendium.com/browse/fda/Busulfan/d6c5bc4ea1850a4acb291fe623fc5dc7?reference=1,1998.0,CS(=O)(=O)OCCCCOS(C)(=O)=O
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Intramuscular,"EMA approval document: Public Assessment Report EMA/586324/2020; EMEA/H/C/004976/0000, page:119 PDF 8611k",https://www.pharmapendium.com/browse/ema/Cabotegravir Sodium/7d31e8568fdb1789517380a5b98893eb?reference=119,2020.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Cangrelor,CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O,Hyperbilirubinaemia,Human,-6.6020599913279625,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 204958/S-000 Part 09, page:124 PDF 20811k",https://www.pharmapendium.com/browse/fda/Cangrelor/059f5cca64999597a4b3d7dc749ffc99?reference=124,2011.0,CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[CH]1O[CH](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[CH](O)[CH]1O
Cariprazine Hydrochloride,CN(C)C(=O)N[C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl,Hyperbilirubinaemia,Human,-1.0791812460476249,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/353055/2017; EMEA/H/C/002770/0000, page:125 PDF 5015k",https://www.pharmapendium.com/browse/ema/Cariprazine Hydrochloride/7f73abc0bee1aef3befa5b082ff2f327?reference=125,2017.0,CN(C)C(=O)N[CH]1CC[CH](CC1)CCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl
Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Label 020297/S-018, page:17 PDF 381k",https://www.pharmapendium.com/browse/fda/Carvedilol/5115e926dd2bdc8b14f2999964897b49?reference=17,2005.0,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Hyperbilirubinaemia,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050749/S-000 Part 03, page:77 PDF 3222k",https://www.pharmapendium.com/browse/fda/Cefdinir/212ed378c202b7d2419ca84211634faa?reference=77,1996.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Cefepime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Hyperbilirubinaemia,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050679 Part 03, page:5 PDF 9346k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/8a86a3464bb77a27a2f4db9b0f3a6652?reference=5,1996.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefixime,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 202091/S-000, page:9 PDF 665k",https://www.pharmapendium.com/browse/fda/Cefixime/3eaea45d1095013613fdc23b10a629cd?reference=9,2013.0,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[CH]1[CH]2SCC(C=C)=C(N2C1=O)C(O)=O
Ceftazidime,[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,Hyperbilirubinaemia,Human,-1.380211241711606,Repeated,Intravenous,"FDA approval package document: Label 050823/S-000, page:12 PDF 492k",https://www.pharmapendium.com/browse/fda/Ceftazidime/5832764d26de859ede48afc9c51219f5?reference=12,2011.0,[H][C]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[CH]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Hyperbilirubinaemia,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/170114/2015; EMEA/H/C/003819/0000, page:84 PDF 3461k",https://www.pharmapendium.com/browse/ema/Ceritinib/625fcc14a77690a19eb6362758b85c7e?reference=84,2015.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Intravenous,"FDA approval package document: Medical Officer Review 019847, page:7 PDF 1356k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/411f34f7a12f980eab321d0d90346ffc?reference=7,1997.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Citalopram Hydrobromide,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Hyperbilirubinaemia,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020822/S-042; 021046/S-019 Part 02, page:26 PDF 436k",https://www.pharmapendium.com/browse/fda/Citalopram Hydrobromide/4b374a2e2e10917b9d0839e1502121b5?reference=26,2012.0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 11, page:60 PDF 23631k",https://www.pharmapendium.com/browse/fda/Cladribine/cdf7c590901bed412a0ba7bd776ef517?reference=60,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,Hyperbilirubinaemia,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 050662 Part 03, page:30 PDF 3924k",https://www.pharmapendium.com/browse/fda/Clarithromycin/2585278e38d95568e9b979a49a1acca1?reference=30,1995.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(C[CH](C)C(=O)[CH](C)[CH](O)[C]1(C)O)OC
Clofarabine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,Hyperbilirubinaemia,Human,-2.568201724066995,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/784815/2012; EMEA/H/C/613/A46/033, page:8 PDF 181k",https://www.pharmapendium.com/browse/ema/Clofarabine/a26194429f501d87eab967e10e56def2?reference=8,2011.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1O[CH](CO)[CH](O)[CH]1F
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/609914/2013; EMEA/H/C/002572/0000, page:72 PDF 1120k",https://www.pharmapendium.com/browse/ema/Cobicistat/0b17670219c561c8ad7f563892377dc6?reference=72,2013.0,CC(C)C1=NC(CN(C)C(=O)N[CH](CCN2CCOCC2)C(=O)N[CH](CC[CH](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Copanlisib Dihydrochloride,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1,Hyperbilirubinaemia,Human,-1.4471580313422192,Repeated,Intravenous,"FDA approval package document: Approval Package 209936/S-000 Part 02, page:96 PDF 11850k",https://www.pharmapendium.com/browse/fda/Copanlisib Dihydrochloride/3a7a918dba0779ad831f58c4b35fbbbb?reference=96,2017.0,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1
Crizotinib,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/497137/2012; EMEA/H/C/002489, page:63 PDF 1174k",https://www.pharmapendium.com/browse/ema/Crizotinib/03002030fc9de8da9d419fa9fadd0255?reference=63,2012.0,C[CH](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl
Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 050716/S-025; 050715/S-024, page:26 PDF 419k",https://www.pharmapendium.com/browse/fda/Cyclosporine/602ee4f3aac2978b4dba431c19279f8c?reference=26,2006.0,CC[CH]1NC(=O)[CH]([CH](O)[CH](C)C\C=C\C)N(C)C(=O)[CH](C(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CC(C)C)N(C)C(=O)[CH](NC(=O)[CH](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Daclatasvir Dihydrochloride,COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,Hyperbilirubinaemia,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206843/S-000 Part 07, page:3 PDF 14260k",https://www.pharmapendium.com/browse/fda/Daclatasvir Dihydrochloride/c69c158f630b83ec03f0f8f8704a8656?reference=3,2014.0,COC(=O)NC(C(C)C)C(=O)N1CCC[CH]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[CH]1CCCN1C(=O)C(NC(=O)OC)C(C)C
Dacomitinib,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,Hyperbilirubinaemia,Human,-1.6532125137753437,Repeated,Oral,"FDA approval package document: Approval Package 211288/S-000 Part 05, page:24 PDF 1028k",https://www.pharmapendium.com/browse/fda/Dacomitinib/6d4eba7f3bd836c0b0446d7c29ede1d8?reference=24,2018.0,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Daptomycin,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,Hyperbilirubinaemia,Human,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 208385/S-000 Part 02, page:7 PDF 370k",https://www.pharmapendium.com/browse/fda/Daptomycin/5188a30b0d2c1bd8e60f6737ac1e27c3?reference=7,2016.0,CCCCCCCCCC(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC(O)=O)C(=O)N[CH]1[CH](C)OC(=O)[CH](CC(=O)C2=C(N)C=CC=C2)NC(=O)[CH](NC(=O)[CH](CO)NC(=O)CNC(=O)[CH](CC(O)=O)NC(=O)[CH](C)NC(=O)[CH](CC(O)=O)NC(=O)[CH](CCCN)NC(=O)CNC1=O)[CH](C)CC(O)=O
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Hyperbilirubinaemia,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021976/S-000 Part 02, page:112 PDF 5706k",https://www.pharmapendium.com/browse/fda/Darunavir Ethanolate/4e04c53da33bc28af175a4f8ed94ab9d?reference=112,2006.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Dasatinib,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1,Hyperbilirubinaemia,Human,-2.146128035678238,Repeated,Oral,"EMA approval document: Scientific Discussion EMEA/H/C/709/II/02, page:13 PDF 197k",https://www.pharmapendium.com/browse/ema/Dasatinib/6a505c33a5e4e71a2d972ff1ca324d90?reference=13,2007.0,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/763315/2016; EMEA/H/C/000670/P46/060.1, page:84 PDF 2575k",https://www.pharmapendium.com/browse/ema/Deferasirox/84caa1d7e3747e30027b83e9c1c039ab?reference=84,2016.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/55567/2014; EMEA/H/C/002552, page:91 PDF 4324k",https://www.pharmapendium.com/browse/ema/Delamanid/e0682a9e8072d93e83504aa96dac2c8e?reference=91,2013.0,C[C]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O
Diclofenac Sodium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019201/S-001, S-002, S-003, S-005, S-007, S-009, S-010, S-013, S-014, S-015, S-019, S-021 Part 05, page:43 PDF 6101k",https://www.pharmapendium.com/browse/fda/Diclofenac Sodium/f085f32441bae56f520b20bdc6c36284?reference=43,1988.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diltiazem Hydrochloride,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,Hyperbilirubinaemia,Human,-2.681241237375587,Repeated,Oral,"FDA approval package document: Approval Package 019471/S-004 Part 03, page:1 PDF 4896k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/2a72f48a5d5e28ae7d6221fc0b1a0ab7?reference=1,1988.0,COC1=CC=C(C=C1)[CH]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[CH]1OC(C)=O
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hyperbilirubinaemia,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:6 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=6,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Donepezil Hydrochloride,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1,Hyperbilirubinaemia,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 022568/S-000, page:6 PDF 940k",https://www.pharmapendium.com/browse/fda/Donepezil Hydrochloride/30602ceb45c3031c10b630c68c395ae5?reference=6,2010.0,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Hyperbilirubinaemia,Human,-2.6989700043360187,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/594074/2014; EMEA/H/000891/P46/030, page:14 PDF 1202k",https://www.pharmapendium.com/browse/ema/Doripenem/12f2a00b81318441b7b1c88fec60490b?reference=14,2014.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Doxepin Hydrochloride,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=CC=C12,Hyperbilirubinaemia,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Label 022036/S-000, page:8 PDF 462k",https://www.pharmapendium.com/browse/fda/Doxepin Hydrochloride/63f1ba282c95744b407a45389e65d3a1?reference=8,2010.0,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=CC=C12
Duvelisib,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 211155/S-000 Part 03, page:86 PDF 1175k",https://www.pharmapendium.com/browse/fda/Duvelisib/487be2bbb254ac57779f07ef4c3747d4?reference=86,2018.0,C[CH](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 021360/S-006, page:61 PDF 4419k",https://www.pharmapendium.com/browse/fda/Efavirenz/ce317f2f01793e8eb8d66f20846f154b?reference=61,2004.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Elvitegravir,COC1=CC2=C(C=C1CC1=CC=CC(Cl)=C1F)C(=O)C(=CN2[C@H](CO)C(C)C)C(O)=O,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/701401/2013; EMEA/H/C/002577/0000, page:84 PDF 3125k",https://www.pharmapendium.com/browse/ema/Elvitegravir/622c06d3f25e6b79ede48d40022d38fb?reference=84,2013.0,COC1=CC2=C(C=C1CC1=CC=CC(Cl)=C1F)C(=O)C(=CN2[CH](CO)C(C)C)C(O)=O
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/137741/2014; EMEA/H/C/002677/0000, page:77 PDF 1395k",https://www.pharmapendium.com/browse/ema/Empagliflozin/436354e1f4b6b84ebc2d059cab3caf56?reference=77,2014.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Emtricitabine,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 594k",https://www.pharmapendium.com/browse/ema/Emtricitabine/a2f94b480c18360a9c7d783b8cfc8a4a?reference=7,2020.0,NC1=NC(=O)N(C=C1F)[CH]1CS[CH](CO)O1
Encainide,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 018981/S-001 Part 07, page:28 PDF 5601k",https://www.pharmapendium.com/browse/fda/Encainide/42d113f86e2c3499080256c9e5120685?reference=28,1989.0,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
Eravacycline dihydrochloride,[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Hyperbilirubinaemia,Human,-1.0791812460476249,Repeated,Intravenous,"EMA approval document: ANNEX I, page:6 PDF 460k",https://www.pharmapendium.com/browse/ema/Eravacycline dihydrochloride/29e6ba06c2408657779f92ebb7f2642b?reference=6,2019.0,[H][C]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Erlotinib Hydrochloride,COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/657134/2011; EMEA/H/C/000618/II/0020, page:38 PDF 1063k",https://www.pharmapendium.com/browse/ema/Erlotinib Hydrochloride/0710958c7d3dcd5c76c13e962d46333b?reference=38,2011.0,COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC
Esomeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)[S@@](=O)CC1=NC=C(C)C(OC)=C1C,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 022101/S-000, page:7 PDF 1747k",https://www.pharmapendium.com/browse/fda/Esomeprazole Magnesium/db2013fb81f87cc67d86cb99ff99b37c?reference=7,2008.0,COC1=CC=C2[N-]C(=NC2=C1)[S](=O)CC1=NC=C(C)C(OC)=C1C
Esomeprazole Sodium,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 021689/S-007, page:9 PDF 284k",https://www.pharmapendium.com/browse/fda/Esomeprazole Sodium/1c22435c698e9787f474311d5feda16d?reference=9,2006.0,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 07, page:1 PDF 4550k",https://www.pharmapendium.com/browse/fda/Etodolac/b2d3917f5dc5458cceb33c6f69f0163b?reference=1,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Hyperbilirubinaemia,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022345/S-000 Part 09, page:13 PDF 798k",https://www.pharmapendium.com/browse/fda/Ezogabine/32ffc5ac0f220009d9a5886e136f3359?reference=13,2011.0,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Famciclovir,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O,Hyperbilirubinaemia,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Medical Officer Review 020363, page:19 PDF 1407k",https://www.pharmapendium.com/browse/fda/Famciclovir/d4874c5cf052c8ae39ef4000f7aec5ca?reference=19,1996.0,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019304 Part 03, page:18 PDF 7698k",https://www.pharmapendium.com/browse/fda/Fenofibrate/7c467e5c47086a300ef271deadab1c7d?reference=18,1993.0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 01, page:20 PDF 743k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/7282c9edf57b7af5577d3d55b966b526?reference=20,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/857570/2011; EMEA/H/C/2087, page:65 PDF 966k",https://www.pharmapendium.com/browse/ema/Fidaxomicin/0ddc1ba8cfbbbb4f77b87c8f806ab0ef?reference=65,2011.0,[H][C]1(C\C=C(C)\C=C(C)\[CH](O[C]2([H])OC(C)(C)[CH](OC(=O)C(C)C)[CH](O)[CH]2O)[CH](CC)\C=C(C)\[CH](O)C\C=C\C=C(CO[CH]2O[CH](C)[CH](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[CH](O)[CH]2OC)\C(=O)O1)[CH](C)O
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Pharmacology Review 018936/S-064 Part 02, page:11 PDF 1165k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/68c522a4383a3dc2782e3a682072e421?reference=11,,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Hyperbilirubinaemia,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 021192/S-019 Part 01, page:12 PDF 804k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/912bcb0c04151b62b35994f63183a4d8?reference=12,2012.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Fondaparinux Sodium,CO[C@H]1O[C@H](COS([O-])(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS([O-])(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS([O-])(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS([O-])(=O)=O)[C@H](O)[C@H]4O)C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]3NS([O-])(=O)=O)[C@H](O)[C@H]2OS([O-])(=O)=O)C([O-])=O)[C@H](O)[C@H]1NS([O-])(=O)=O,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Subcutaneous,"EMA approval document: ANNEX I, page:16 PDF 1162k",https://www.pharmapendium.com/browse/ema/Fondaparinux Sodium/43bbe971badaf392d3fd5107a47411b0?reference=16,2011.0,CO[CH]1O[CH](COS([O-])(=O)=O)[CH](O[CH]2O[CH]([CH](O[CH]3O[CH](COS([O-])(=O)=O)[CH](O[CH]4O[CH]([CH](O[CH]5O[CH](COS([O-])(=O)=O)[CH](O)[CH](O)[CH]5NS([O-])(=O)=O)[CH](O)[CH]4O)C([O-])=O)[CH](OS([O-])(=O)=O)[CH]3NS([O-])(=O)=O)[CH](O)[CH]2OS([O-])(=O)=O)C([O-])=O)[CH](O)[CH]1NS([O-])(=O)=O
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Hyperbilirubinaemia,Human,-2.6232492903979003,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/473724/2015; EMEA/H/C/003791/II/0001, page:40 PDF 2703k",https://www.pharmapendium.com/browse/ema/Ibrutinib/3509c053a50f597a98dadfa00620acfc?reference=40,2015.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205858/S-000, page:72 PDF 20161k",https://www.pharmapendium.com/browse/fda/Idelalisib/1b92abd14a9a906b26c35d7143db09e3?reference=72,2013.0,CC[CH](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020966, page:9 PDF 2870k",https://www.pharmapendium.com/browse/fda/Itraconazole/e816200206ea1ca7ddfdaba8985ae24d?reference=9,1998.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019816/S-001, S-002 Part 03, page:23 PDF 8286k",https://www.pharmapendium.com/browse/fda/Ketoprofen/dd45df8904cef875c768de355112741c?reference=23,1993.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Hyperbilirubinaemia,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021003/S-000; 021004/S-000 Part 02, page:12 PDF 1190k",https://www.pharmapendium.com/browse/fda/Lamivudine/7c6e1619f95c9fc2e29616fe111898a9?reference=12,1998.0,NC1=NC(=O)N(C=C1)[CH]1CS[CH](CO)O1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Hyperbilirubinaemia,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020764/S-020; 020241/S-027 Part 05, page:13 PDF 1437k",https://www.pharmapendium.com/browse/fda/Lamotrigine/4347e1db59c4b9082a2b357826105532?reference=13,2006.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Hyperbilirubinaemia,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Approval Package 078730/S-000 Part 02, page:8 PDF 368k",https://www.pharmapendium.com/browse/fda/Lansoprazole/c798ec4173255d287342e21e7070f635?reference=8,2010.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Hyperbilirubinaemia,Human,-1.4471580313422192,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/108277/2017; EMEA/H/C/000717/II/0089/G, page:61 PDF 3010k",https://www.pharmapendium.com/browse/ema/Lenalidomide/53d7d52fce5760b22f1840ede974c260?reference=61,2017.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Letermovir,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F,Hyperbilirubinaemia,Human,-2.681241237375587,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/490007/2017; EMEA/H/C/004536/0000, page:101 PDF 3109k",https://www.pharmapendium.com/browse/ema/Letermovir/180cdbdeec542a8be5c987509259fe83?reference=101,2017.0,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[CH](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hyperbilirubinaemia,Human,-2.8750612633917,Repeated,Oral/intravenous,"FDA approval package document: Approval Package 020634/S-027; 020635/S-026 Part 01, page:31 PDF 7572k",https://www.pharmapendium.com/browse/fda/Levofloxacin/2ddd675441d5e0ac8cdc12a1cb8ea6ec?reference=31,2003.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201280/S-000 Part 04, page:94 PDF 5485k",https://www.pharmapendium.com/browse/fda/Linagliptin/4040600348d5f8e24c3f5c858638a448?reference=94,2010.0,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[CH](N)C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hyperbilirubinaemia,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 206321/S-000 Part 09, page:11 PDF 671k",https://www.pharmapendium.com/browse/fda/Liraglutide/34530c9056f6fe0e2762f4e4e8c07a31?reference=11,2014.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lisinopril,[H][C@]1(CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(O)=O,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 019777/S-007, S-010, S-014, S-016, S-019, S-021, S-022, S-023, S-024, S-025; 019888/S-007, S-009, S-014, S-021; 019558 Part 06, page:51 PDF 6368k",https://www.pharmapendium.com/browse/fda/Lisinopril/dc7ab638889737a8c43d7d7621a45482?reference=51,1988.0,[H][C]1(CCCN1C(=O)[CH](CCCCN)N[CH](CCC1=CC=CC=C1)C(O)=O)C(O)=O
Loperamide Hydrochloride,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019487/S-007 Part 02, page:44 PDF 6802k",https://www.pharmapendium.com/browse/fda/Loperamide Hydrochloride/37dbb74fd531640da4b651274266df32?reference=44,1988.0,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 208984/S-017 Part 02, page:10 PDF 406k",https://www.pharmapendium.com/browse/fda/Maraviroc/13a38ddf3198ad19f88ef484538c815a?reference=10,2016.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Melatonin,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1,Hyperbilirubinaemia,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 340k",https://www.pharmapendium.com/browse/ema/Melatonin/ae4b46a64450e49e56a410e48d600edd?reference=6,2021.0,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Hyperbilirubinaemia,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207233/S-000 Part 04, page:49 PDF 9738k",https://www.pharmapendium.com/browse/fda/Meloxicam/0caf0c63e10542b81af2c271442ab2d4?reference=49,2015.0,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Memantine Hydrochloride,[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021487/S-000 Part 03, page:36 PDF 1746k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/291c029e978a009ff3187ec5aa81c284?reference=36,2003.0,[H][C]12C[C]3(C)C[C](C)(C1)C[C](N)(C2)C3
Menadiol Sodium Diphosphate,CC1=CC(OP([O-])([O-])=O)=C2C=CC=CC2=C1OP([O-])([O-])=O,Hyperbilirubinaemia,Human,0.0,Repeated,Parenteral,"FDA approval package document: Approval Package 005725, page:24 PDF 3199k",https://www.pharmapendium.com/browse/fda/Menadiol Sodium Diphosphate/01de88c194679396ea82d14013b28f90?reference=24,1945.0,CC1=CC(OP([O-])([O-])=O)=C2C=CC=CC2=C1OP([O-])([O-])=O
Menadione Sodium Bisulfite,CC1(CC(=O)C2=C(C=CC=C2)C1=O)S([O-])(=O)=O,Hyperbilirubinaemia,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 002694, page:7 PDF 833k",https://www.pharmapendium.com/browse/fda/Menadione Sodium Bisulfite/be3c8edeeca303f211b5c3a49915bb40?reference=7,1940.0,CC1(CC(=O)C2=C(C=CC=C2)C1=O)S([O-])(=O)=O
Mercaptopurine,S=C1NC=NC2=C1NC=N2,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 205919/S-000, page:4 PDF 1266k",https://www.pharmapendium.com/browse/fda/Mercaptopurine/c434c89bc8f0dc47ad8a93b7dfc72c7c?reference=4,2014.0,S=C1NC=NC2=C1NC=N2
Meropenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Hyperbilirubinaemia,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 050706 Part 01, page:39 PDF 2011k",https://www.pharmapendium.com/browse/fda/Meropenem/5598779ef002a770e637b1cb2a5ea2ba?reference=39,1995.0,[H][C]12[CH](C)C(S[CH]3CN[CH](C3)C(=O)N(C)C)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Hyperbilirubinaemia,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 022000/S-005 Part 02, page:119 PDF 14664k",https://www.pharmapendium.com/browse/fda/Mesalamine/6dd5c45b6e24648a96b0fc7c1fcf31af?reference=119,2011.0,NC1=CC(C(O)=O)=C(O)C=C1
Methyltestosterone,[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(C)O,Hyperbilirubinaemia,Human,-1.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Methyltestosterone-0023   ---   JOURNAL:British Medical Journal   PAGES:259   VOLUME:1,,1959.0,[H][C]12CCC3=CC(=O)CC[C]3(C)[C]1([H])CC[C]1(C)[C]2([H])CC[C]1(C)O
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000 Part 04, page:7 PDF 7162k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/bed36c7c52cf41ed159f180586049913?reference=7,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Midostaurin,[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.0,Repeated,Oral,"FDA approval package document: Label 207997/S-001, S-002, page:9 PDF 502k",https://www.pharmapendium.com/browse/fda/Midostaurin/c1d109a905f81fa9940763125af9da0c?reference=9,2017.0,[H][C]12C[CH]([CH](OC)[C](C)(O1)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1
Miltefosine,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204684/S-000 Part 01, page:30 PDF 685k",https://www.pharmapendium.com/browse/fda/Miltefosine/d578768c04ada62a2f887e64d74423fb?reference=30,2014.0,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
Mometasone Furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 021067/S-000 Part 01, page:77 PDF 5737k",https://www.pharmapendium.com/browse/fda/Mometasone Furoate/4572c2b9e18a55979584166ebdcf91df?reference=77,2005.0,[H][C]12C[CH](C)[C](OC(=O)C3=CC=CO3)(C(=O)CCl)[C]1(C)C[CH](O)[C]1(Cl)[C]2([H])CCC2=CC(=O)C=C[C]12C
Moxifloxacin Hydrochloride,[H][C@@]12CCCN[C@]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,Hyperbilirubinaemia,Human,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021085/S-061; 021277/S-057 Part 02, page:14 PDF 435k",https://www.pharmapendium.com/browse/fda/Moxifloxacin Hydrochloride/57b5a0bc69de3088593f4933e17c69a3?reference=14,2016.0,[H][C]12CCCN[C]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1,Hyperbilirubinaemia,Human,-3.4771212547196626,Repeated,Intravenous,"EMA approval document: ANNEX I, page:32 PDF 1007k",https://www.pharmapendium.com/browse/ema/Mycophenolate Mofetil/98df93bfd743b8a911ebd23509e3398a?reference=32,2020.0,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
Nebivolol Hydrochloride,[H][C@@]1(CCC2=CC(F)=CC=C2O1)[C@H](O)CNC[C@@H](O)[C@]1([H])CCC2=CC(F)=CC=C2O1,Hyperbilirubinaemia,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021742/S-000 Part 07, page:44 PDF 5831k",https://www.pharmapendium.com/browse/fda/Nebivolol Hydrochloride/c22a1b61a9df4fdde7d3660c5a0ba709?reference=44,2007.0,[H][C]1(CCC2=CC(F)=CC=C2O1)[CH](O)CNC[CH](O)[C]1([H])CCC2=CC(F)=CC=C2O1
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 201152/S-000, page:4 PDF 507k",https://www.pharmapendium.com/browse/fda/Nevirapine/18b79028e6ff80260708a5a806a0b4ce?reference=4,2011.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022068/S-000, page:33 PDF 7023k",https://www.pharmapendium.com/browse/fda/Nilotinib Hydrochloride Monohydrate/f464341f37b8bc678bc8d0b094d65dc9?reference=33,2007.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nitric Oxide,[N]=O,Hyperbilirubinaemia,Human,-1.3010299956639813,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 020845 Part 03, page:2 PDF 3173k",https://www.pharmapendium.com/browse/fda/Nitric Oxide/0111a8354b24d9bcb931fedb9f23043a?reference=2,1997.0,[N]=O
"Nitrofurantoin, Macrocrystalline",O=C1CN(C(=O)N1)\N=C\C1=CC=C(O1)N(=O)=O,Hyperbilirubinaemia,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 016620/S-064, page:30 PDF 2554k","https://www.pharmapendium.com/browse/fda/Nitrofurantoin, Macrocrystalline/87b6846f59ea68c204bf40dd016affea?reference=30",2003.0,O=C1CN(C(=O)N1)\N=C\C1=CC=C(O1)N(=O)=O
Novobiocin Sodium,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C([O-])=C(NC(=O)C2=CC=C(O)C(C\C=C(\C)C)=C2)C(=O)O3)OC1(C)C,Hyperbilirubinaemia,Human,-3.0,Repeated,Oral,"FDA approval package document: Review 010307, page:4 PDF 2603k",https://www.pharmapendium.com/browse/fda/Novobiocin Sodium/eb662eb5ed16df5d2d42ce0af0829e13?reference=4,1969.0,CO[CH]1[CH](OC(N)=O)[CH](O)[CH](OC2=C(C)C3=C(C=C2)C([O-])=C(NC(=O)C2=CC=C(O)C(C\C=C(\C)C)=C2)C(=O)O3)OC1(C)C
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Hyperbilirubinaemia,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207999/S-000 Part 04, page:76 PDF 18785k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/fd9575acfa8e5dadbfa0aa39e5adfd26?reference=76,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Ofloxacin,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hyperbilirubinaemia,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 019735/S-002, S-005, S-006, S-017, S-024, S-035, S-041, S-042; 020087/S-017 Part 14, page:35 PDF 7211k",https://www.pharmapendium.com/browse/fda/Ofloxacin/2c51783bd554e63801f2040c23dc2f9b?reference=35,1990.0,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Hyperbilirubinaemia,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 020592/S-035, S-039, S-040, S-041, S-049, S-053; 021086/S-021; 021253/S-037 Part 03, page:22 PDF 487k",https://www.pharmapendium.com/browse/fda/Olanzapine/80b278fba61b9898be26d93eb05867d9?reference=22,2010.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019810/S-002, S-007, S-036, S-037, S-009, S-010, S-022, S-035, S-019, S-023, S-025, S-033, S-034; 050662/S-010 Part 14, page:26 PDF 5805k",https://www.pharmapendium.com/browse/fda/Omeprazole/12831b780150efb4ea15f3657403c1b9?reference=26,1990.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021229/S-000, page:176 PDF 20401k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/42ffe48b5d32d8a231f5c085c007aa78?reference=176,2003.0,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Oxaprozin,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018841/S-003, S-001, S-002, S-004, S-005 Part 05, page:27 PDF 4206k",https://www.pharmapendium.com/browse/fda/Oxaprozin/ffb9582bcf1e839d7253b4d540be07e0?reference=27,1992.0,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1
Ozanimod Hydrochloride,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,Hyperbilirubinaemia,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209899/S-000 Part 03, page:29 PDF 10208k",https://www.pharmapendium.com/browse/fda/Ozanimod Hydrochloride/7164e6e8c274a00edb449ad7de1788ce?reference=29,2019.0,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[CH](NCCO)C2=CC=C1)C#N
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Hyperbilirubinaemia,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Label 077395 Part 02, page:9 PDF 4432k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/1a8809c0636779bdcb24a97a2b97ae6f?reference=9,2006.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Hyperbilirubinaemia,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022465/S-000, page:68 PDF 1560k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/893f6f8879191ff31ae434f60b8e4e98?reference=68,2009.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Pemigatinib,CCN1C(=O)N(CC2=C1C1=C(NC(CN3CCOCC3)=C1)N=C2)C1=C(F)C(OC)=CC(OC)=C1F,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 213736/S-000 Part 05, page:33 PDF 1537k",https://www.pharmapendium.com/browse/fda/Pemigatinib/d0708ed22020055166ccbd29f5a1f7f6?reference=33,2020.0,CCN1C(=O)N(CC2=C1C1=C(NC(CN3CCOCC3)=C1)N=C2)C1=C(F)C(OC)=CC(OC)=C1F
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Hyperbilirubinaemia,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 022363/S-008, S-009 Part 01, page:12 PDF 692k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/10e441706bdc77551b502e590746b3cc?reference=12,2012.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Pomalidomide,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1,Hyperbilirubinaemia,Human,-0.6020599913279624,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/427059/2013; EMEA/H/C/002682, page:59 PDF 1736k",https://www.pharmapendium.com/browse/ema/Pomalidomide/f8af3f97d1313e5c12f4634904aa18f4?reference=59,2013.0,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/75051/2015; EMEA/H/C/000610/X/0033, page:52 PDF 1890k",https://www.pharmapendium.com/browse/ema/Posaconazole/c7384c4efa7992daed05b131bff50b6e?reference=52,2014.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pralsetinib,CO[C@@]1(CC[C@@H](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 213721/S-000 Part 06, page:33 PDF 7982k",https://www.pharmapendium.com/browse/fda/Pralsetinib/26a0773d49143819947e790c5be9ae0d?reference=33,2020.0,CO[C]1(CC[CH](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[CH](C)C1=CC=C(N=C1)N1C=C(F)C=N1
Pravastatin Sodium,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)OC(=O)[C@@H](C)CC,Hyperbilirubinaemia,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-062 Part 02, page:5 PDF 3050k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/9abdc43bcffbab44680339cfab4a9fb0?reference=5,2012.0,[H][C]12[CH](C[CH](O)C=C1C=C[CH](C)[CH]2CC[CH](O)C[CH](O)CC([O-])=O)OC(=O)[CH](C)CC
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Hyperbilirubinaemia,Human,-2.8195439355418688,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209501/S-000 Part 05, page:16 PDF 516k",https://www.pharmapendium.com/browse/fda/Pregabalin/216d8308cd8d84eedbddc2e79161de51?reference=16,2017.0,CC(C)C[CH](CN)CC(O)=O
Pretomanid,FC(F)(F)OC1=CC=C(CO[C@@H]2COC3=NC(=CN3C2)N(=O)=O)C=C1,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:8 PDF 306k",https://www.pharmapendium.com/browse/ema/Pretomanid/b1f2d25a3bc79a74ac5a0f45b4aaffc4?reference=8,2021.0,FC(F)(F)OC1=CC=C(CO[CH]2COC3=NC(=CN3C2)N(=O)=O)C=C1
Quizartinib Dihydrochloride,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1,Hyperbilirubinaemia,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/602286/2019; EMEA/H/C/004468/0000, page:89 PDF 5534k",https://www.pharmapendium.com/browse/ema/Quizartinib Dihydrochloride/e5a1774afc92002d3e3710192a619e0e?reference=89,2019.0,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Hyperbilirubinaemia,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical Officer Review 020973, page:29 PDF 1524k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/8a376a97d1307c2727bbe4bd44ffed8c?reference=29,1998.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022145/S-000 Part 03, page:9 PDF 2078k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/9cd063dfa307884e9ecb03bd9d0b45ce?reference=9,2011.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Ramelteon,CCC(=O)NCC[C@@H]1CCC2=CC=C3OCCC3=C12,Hyperbilirubinaemia,Human,-1.806179973983887,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021782/S-000, page:117 PDF 9492k",https://www.pharmapendium.com/browse/fda/Ramelteon/a3f84388351ef23f52c8051f992e9779?reference=117,2005.0,CCC(=O)NCC[CH]1CCC2=CC=C3OCCC3=C12
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Hyperbilirubinaemia,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Office Director Memo 203085/S-000, page:10 PDF 1567k",https://www.pharmapendium.com/browse/fda/Regorafenib/4584cc610e46797b24c2b9bf3d4f4e92?reference=10,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.0,Repeated,Intravenous,"EMA approval document: Public Assessment Report, page:143 PDF 5413k",https://www.pharmapendium.com/browse/ema/Remdesivir/29484e8f593af0a4f0b7e224d45ebbd2?reference=143,2020.0,CCC(CC)COC(=O)[CH](C)N[P](=O)(OC[CH]1O[C](C#N)([CH](O)[CH]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Hyperbilirubinaemia,Human,-3.146128035678238,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 831k",https://www.pharmapendium.com/browse/ema/Ribavirin/5f3d429ef85eca746a2b1385496d70be?reference=12,2019.0,NC(=O)C1=NN(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Rifampin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(C)CC1)=C2O,Hyperbilirubinaemia,Human,-1.2041199826559248,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: Para-Aminosalicylic Acid-0064   ---   DOI:10.1136/pgmj.56.652.135   JOURNAL:Postgraduate Medical Journal   PAGES:135   VOLUME:56,http://dx.doi.org/10.1136/pgmj.56.652.135,1980.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C(\C=N\N1CCN(C)CC1)=C2O
Rilpivirine Hydrochloride,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202022/S-000, page:36 PDF 1064k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/9ced65a4af087352a74203f63a45eb54?reference=36,2011.0,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Ripretinib,CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 213973/S-000 Part 01, page:22 PDF 635k",https://www.pharmapendium.com/browse/fda/Ripretinib/f351a78332c0b1592ffce27198c9e71d?reference=22,2020.0,CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Hyperbilirubinaemia,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020272/S-036 Part 12, page:17 PDF 2715k",https://www.pharmapendium.com/browse/fda/Risperidone/00d3cf228e8451f91c5b7f27a2f0be5a?reference=17,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hyperbilirubinaemia,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 01, page:44 PDF 1333k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/bc6e880b062db2c78b661508027015fd?reference=44,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Hyperbilirubinaemia,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-024 Part 03, page:19 PDF 933k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/fd6f850669161bf26eb7261f0808b3aa?reference=19,2012.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,Hyperbilirubinaemia,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207947/S-000 Part 05, page:6 PDF 601k",https://www.pharmapendium.com/browse/fda/Selexipag/0a014815d9b037d06801f9864d8abfcb?reference=6,2015.0,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
Simeprevir Sodium,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,Hyperbilirubinaemia,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205123/S-000 Part 14, page:7 PDF 2421k",https://www.pharmapendium.com/browse/fda/Simeprevir Sodium/fd82a4a1819b234234eb96cdaa34a562?reference=7,2013.0,[H][C]12C[C]1(NC(=O)[C]1([H])C[CH](C[C]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1
Sodium Oxybate,OCCCC([O-])=O,Hyperbilirubinaemia,Human,-3.9542425094393248,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021196/S-000 Part 10, page:32 PDF 1551k",https://www.pharmapendium.com/browse/fda/Sodium Oxybate/8284148121cddd830616b0e2c1af886e?reference=32,2001.0,OCCCC([O-])=O
Sofosbuvir,CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/688774/2013; EMEA/H/C/002798/0000, page:89 PDF 1705k",https://www.pharmapendium.com/browse/ema/Sofosbuvir/1032262fbb076109fe76e6135bc7910e?reference=89,2013.0,CC(C)OC(=O)[CH](C)NP(=O)(OC[CH]1O[CH](N2C=CC(=O)NC2=O)[C](C)(F)[CH]1O)OC1=CC=CC=C1
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Hyperbilirubinaemia,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 14, page:35 PDF 9336k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/5ca35442c7a6262bcfb861e4be5ed2ab?reference=35,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical Officer Review 050708, page:89 PDF 3016k",https://www.pharmapendium.com/browse/fda/Tacrolimus/75646250a5469f39fb3d1f2a54123990?reference=89,1994.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,Hyperbilirubinaemia,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: ANNEX I, page:21 PDF 1155k",https://www.pharmapendium.com/browse/ema/Telaprevir/6defe160000c04f95cf83eb9c075ef62?reference=21,2016.0,[H][C]12CCC[C]1([H])[CH](N(C2)C(=O)[CH](NC(=O)[CH](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[CH](CCC)C(=O)C(=O)NC1CC1
Ticagrelor,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1,Hyperbilirubinaemia,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Assessment Report EMA/7549/2011, page:37 PDF 987k",https://www.pharmapendium.com/browse/ema/Ticagrelor/468f90b35105539d0ccd3a382e7992b7?reference=37,2013.0,CCCSC1=NC(N[CH]2C[CH]2C2=CC=C(F)C(F)=C2)=C2N=NN([CH]3C[CH](OCCO)[CH](O)[CH]3O)C2=N1
Tigecycline,[H][C@@]12CC3=C(C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C,Hyperbilirubinaemia,Human,-1.6989700043360187,Repeated,Intravenous,"EMA approval document: Withdrawal Public Statement EMEA/382036/2008, page:58 PDF 1174k",https://www.pharmapendium.com/browse/ema/Tigecycline/9442a757f05a00f09f95c3359b4cfc6d?reference=58,2008.0,[H][C]12CC3=C(C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C
Tiludronate Disodium,OP([O-])(=O)C(SC1=CC=C(Cl)C=C1)P(O)([O-])=O,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020707/S-000, page:75 PDF 3013k",https://www.pharmapendium.com/browse/fda/Tiludronate Disodium/78e8e520f2d22190bd6ce224470857aa?reference=75,1997.0,OP([O-])(=O)C(SC1=CC=C(Cl)C=C1)P(O)([O-])=O
Tinidazole,CCS(=O)(=O)CCN1C(C)=NC=C1N(=O)=O,Hyperbilirubinaemia,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021618/S-000; 021681/S-000; 021682/S-000 Part 01, page:35 PDF 1565k",https://www.pharmapendium.com/browse/fda/Tinidazole/ef8074e8d0653227e6b5ac94398a11e1?reference=35,2004.0,CCS(=O)(=O)CCN1C(C)=NC=C1N(=O)=O
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Hyperbilirubinaemia,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022292/S-000; 021814/S-005, page:8 PDF 781k",https://www.pharmapendium.com/browse/fda/Tipranavir/e64bd5097e32bb239dcfdbb10f33afad?reference=8,2008.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Tramadol Hydrochloride,COC1=CC(=CC=C1)[C@]1(O)CCCC[C@H]1CN(C)C,Hyperbilirubinaemia,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 020281 Part 04, page:30 PDF 4425k",https://www.pharmapendium.com/browse/fda/Tramadol Hydrochloride/4b70086f27976254a969bfaf0b09086e?reference=30,1995.0,COC1=CC(=CC=C1)[C]1(O)CCCC[CH]1CN(C)C
Trazodone Hydrochloride,ClC1=CC(=CC=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,Hyperbilirubinaemia,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Label 022411/S-000, page:12 PDF 1121k",https://www.pharmapendium.com/browse/fda/Trazodone Hydrochloride/a511d30aeae8c87a776cb787b11bb761?reference=12,2010.0,ClC1=CC(=CC=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
Triamcinolone Acetonide,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Intranasal,"FDA approval package document: Medical/Clinical Review 020120/S-000 Part 01, page:41 PDF 1275k",https://www.pharmapendium.com/browse/fda/Triamcinolone Acetonide/e49c2b26062a1cfbda3e9ade12af25ad?reference=41,2000.0,[H][C]12C[CH]3OC(C)(C)O[C]3(C(=O)CO)[C]1(C)C[CH](O)[C]1(F)[C]2([H])CCC2=CC(=O)C=C[C]12C
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 213411/S-001, page:6 PDF 999k",https://www.pharmapendium.com/browse/fda/Tucatinib/f1a86e7fa41a3766a3afda32e98fe0de?reference=6,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)[C@@H](C(C)C)C(O)=O,Hyperbilirubinaemia,Human,-2.505149978319906,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020665/S-016; 021283/S-001 Part 04, page:1 PDF 1361k",https://www.pharmapendium.com/browse/fda/Valsartan/03fccdae967d0ba20d480ea7dd8479b0?reference=1,2001.0,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)[CH](C(C)C)C(O)=O
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,Hyperbilirubinaemia,Human,-2.9822712330395684,Repeated,Oral,"EMA approval document: Assessment Report EMA/200986/2012; EMEA/H/C/002409, page:78 PDF 1852k",https://www.pharmapendium.com/browse/ema/Vemurafenib/3f4e6b934f558fc729afc31971243828?reference=78,2011.0,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Venetoclax,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 208573/S-020; 208573/S-021 Part 13, page:5 PDF 9744k",https://www.pharmapendium.com/browse/fda/Venetoclax/3488d6fcf4b5e5bdbfa4f42ba6016f00?reference=5,2020.0,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Hyperbilirubinaemia,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Approval Package 020151; 020527 Part 02, page:91 PDF 7315k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/9f634a28eacbefbc406fe3e419e7a3a0?reference=91,1993.0,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hyperbilirubinaemia,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021266/S-000; 021267/S-000 Part 04, page:50 PDF 1582k",https://www.pharmapendium.com/browse/fda/Voriconazole/b91def2fd3ba7fba9e4703146e866659?reference=50,2001.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Hyperbilirubinaemia,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 020547/S-029, page:18 PDF 1194k",https://www.pharmapendium.com/browse/fda/Zafirlukast/244ecd1e992ff73be2fed108af9f0eb5?reference=18,2009.0,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Hyperbilirubinaemia,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 020199 Part 11, page:8 PDF 6994k",https://www.pharmapendium.com/browse/fda/Zalcitabine/a23abfaff31eeb2231f8321ed61f5a7c?reference=8,1992.0,NC1=NC(=O)N(C=C1)[CH]1CC[CH](CO)O1
Zanamivir,[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Hyperbilirubinaemia,Human,-2.7781512503836434,Repeated,Intravenous,"EMA approval document: Public Assessment Report EMA/CHMP/851480/2018; EMEA/H/C/004102/0000, page:111 PDF 2375k",https://www.pharmapendium.com/browse/ema/Zanamivir/0160f7132f67bf85b6bfb2d976c2fd6f?reference=111,2019.0,[H][C]1(OC(=C[CH](NC(N)=N)[CH]1NC(C)=O)C(O)=O)[CH](O)[CH](O)CO
Zanubrutinib,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1,Hyperbilirubinaemia,Human,-2.505149978319906,Repeated,Oral,"FDA approval package document: Approval Package 213217/S-000 Part 02, page:94 PDF 15322k",https://www.pharmapendium.com/browse/fda/Zanubrutinib/29d03225a4fe0c37218e413611217951?reference=94,2019.0,NC(=O)C1=C2NCC[CH](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1
Zidovudine,CC1=CN([C@H]2C[C@H](N=N#N)[C@@H](CO)O2)C(=O)NC1=O,Hyperbilirubinaemia,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 200732/S-000, page:10 PDF 577k",https://www.pharmapendium.com/browse/fda/Zidovudine/9e62d4d01af2595c48ccc71623e931df?reference=10,2011.0,CC1=CN([CH]2C[CH](N=N#N)[CH](CO)O2)C(=O)NC1=O
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Hyperbilirubinaemia,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020471/S-007, page:11 PDF 1360k",https://www.pharmapendium.com/browse/fda/Zileuton/297b2570ca8de0a8b1c5586f78dff481?reference=11,1998.0,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Ziprasidone Hydrochloride,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12,Hyperbilirubinaemia,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020825/S-000 Part 03, page:31 PDF 1609k",https://www.pharmapendium.com/browse/fda/Ziprasidone Hydrochloride/9c5dd9fe6f94b64e603bf9785f72e655?reference=31,1998.0,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12
